> top > docs > PubMed:26028668 > annotations

PubMed:26028668 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
26028668-0#5#15#gene10232 5-15 gene10232 denotes mesothelin
26028668-0#78#82#gene3845 78-82 gene3845 denotes KRAS
26028668-0#39#58#diseaseC0152013 39-58 diseaseC0152013 denotes lung adenocarcinoma
26028668-1#0#10#gene10232 115-125 gene10232 denotes Mesothelin
26028668-1#16#41#gene9308 131-156 gene9308 denotes cell surface glycoprotein
26028668-1#16#41#gene2703 131-156 gene2703 denotes cell surface glycoprotein
26028668-1#139#149#diseaseC0027627 254-264 diseaseC0027627 denotes metastases
26028668-7#47#57#gene10232 1029-1039 gene10232 denotes mesothelin
26028668-7#79#89#gene10232 1061-1071 gene10232 denotes mesothelin
26028668-7#113#123#gene10232 1095-1105 gene10232 denotes mesothelin
26028668-7#21#36#diseaseC0001418 1003-1018 diseaseC0001418 denotes adenocarcinomas
5#15#gene1023239#58#diseaseC0152013 26028668-0#5#15#gene10232 26028668-0#39#58#diseaseC0152013 associated_with mesothelin,lung adenocarcinoma
78#82#gene384539#58#diseaseC0152013 26028668-0#78#82#gene3845 26028668-0#39#58#diseaseC0152013 associated_with KRAS,lung adenocarcinoma
0#10#gene10232139#149#diseaseC0027627 26028668-1#0#10#gene10232 26028668-1#139#149#diseaseC0027627 associated_with Mesothelin,metastases
16#41#gene9308139#149#diseaseC0027627 26028668-1#16#41#gene9308 26028668-1#139#149#diseaseC0027627 associated_with cell surface glycoprotein,metastases
16#41#gene2703139#149#diseaseC0027627 26028668-1#16#41#gene2703 26028668-1#139#149#diseaseC0027627 associated_with cell surface glycoprotein,metastases
47#57#gene1023221#36#diseaseC0001418 26028668-7#47#57#gene10232 26028668-7#21#36#diseaseC0001418 associated_with mesothelin,adenocarcinomas
79#89#gene1023221#36#diseaseC0001418 26028668-7#79#89#gene10232 26028668-7#21#36#diseaseC0001418 associated_with mesothelin,adenocarcinomas
113#123#gene1023221#36#diseaseC0001418 26028668-7#113#123#gene10232 26028668-7#21#36#diseaseC0001418 associated_with mesothelin,adenocarcinomas

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T992 115-125 gene:10232 denotes Mesothelin
T993 254-264 disease:C0027627 denotes metastases
T994 131-156 gene:9308 denotes cell surface glycoprotein
R1 T992 T993 associated_with Mesothelin,metastases
R2 T994 T993 associated_with cell surface glycoprotein,metastases
R3 T994 T993 associated_with cell surface glycoprotein,metastases

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-114 Sentence denotes High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
TextSentencer_T2 115-265 Sentence denotes Mesothelin is a cell surface glycoprotein which is highly expressed in several epithelial cancers and may have a role in cell adhesion and metastases.
TextSentencer_T3 266-413 Sentence denotes In this study, we used prospectively obtained clinical and pathological data to characterize mesothelin expression in advanced lung adenocarcinoma.
TextSentencer_T4 414-605 Sentence denotes Tissue was obtained from patients who underwent molecular profiling of potentially actionable genes on a trial of molecular profiling and targeted therapies in advanced thoracic malignancies.
TextSentencer_T5 606-742 Sentence denotes We immunohistochemically evaluated the intensity, and the percentage of cells expressing mesothelin in 93 advanced lung adenocarcinomas.
TextSentencer_T6 743-801 Sentence denotes The evaluation was blinded for molecular data and outcome.
TextSentencer_T7 802-981 Sentence denotes Mutations of EGFR, KRAS, BRAF, AKT1, PIK3CA and HER2 were assessed by pyrosequencing; HER2 amplification and ALK translocation were assessed by fluorescence in situ hybridization.
TextSentencer_T8 982-1173 Sentence denotes 53% of advanced lung adenocarcinomas expressed mesothelin to some degree; high mesothelin expression, defined as mesothelin positivity in more than 25% of cells, was found in 24% of patients.
TextSentencer_T9 1174-1287 Sentence denotes High mesothelin expression was associated with inferior survival (median 18.2 months vs. 32.9 months; P = 0.014).
TextSentencer_T10 1288-1400 Sentence denotes High mesothelin expression was strongly associated with mutant KRAS (P < 0.0001) and wild-type EGFR (P = 0.002).
TextSentencer_T11 1401-1555 Sentence denotes Our results provide strong rationale to explore anti-mesothelin targeted therapies in advanced lung adenocarcinoma especially in the KRAS-mutant subgroup.
T1 0-114 Sentence denotes High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
T2 115-265 Sentence denotes Mesothelin is a cell surface glycoprotein which is highly expressed in several epithelial cancers and may have a role in cell adhesion and metastases.
T3 266-413 Sentence denotes In this study, we used prospectively obtained clinical and pathological data to characterize mesothelin expression in advanced lung adenocarcinoma.
T4 414-605 Sentence denotes Tissue was obtained from patients who underwent molecular profiling of potentially actionable genes on a trial of molecular profiling and targeted therapies in advanced thoracic malignancies.
T5 606-742 Sentence denotes We immunohistochemically evaluated the intensity, and the percentage of cells expressing mesothelin in 93 advanced lung adenocarcinomas.
T6 743-801 Sentence denotes The evaluation was blinded for molecular data and outcome.
T7 802-981 Sentence denotes Mutations of EGFR, KRAS, BRAF, AKT1, PIK3CA and HER2 were assessed by pyrosequencing; HER2 amplification and ALK translocation were assessed by fluorescence in situ hybridization.
T8 982-1173 Sentence denotes 53% of advanced lung adenocarcinomas expressed mesothelin to some degree; high mesothelin expression, defined as mesothelin positivity in more than 25% of cells, was found in 24% of patients.
T9 1174-1287 Sentence denotes High mesothelin expression was associated with inferior survival (median 18.2 months vs. 32.9 months; P = 0.014).
T10 1288-1400 Sentence denotes High mesothelin expression was strongly associated with mutant KRAS (P < 0.0001) and wild-type EGFR (P = 0.002).
T11 1401-1555 Sentence denotes Our results provide strong rationale to explore anti-mesothelin targeted therapies in advanced lung adenocarcinoma especially in the KRAS-mutant subgroup.

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 39-43 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T2 393-397 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T3 721-725 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T4 998-1002 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T5 1496-1500 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 39-43 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T2 393-397 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T3 721-725 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T4 998-1002 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T5 1496-1500 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T6 414-420 http://purl.obolibrary.org/obo/UBERON_0000479 denotes Tissue